No headlines found.
Globe Newswire (Tue, 5-Sep 7:00 AM ET)
Globe Newswire (Fri, 4-Aug 7:00 AM ET)
Globe Newswire (Fri, 28-Jul 7:00 AM ET)
Globe Newswire (Wed, 26-Jul 7:00 AM ET)
Globe Newswire (Mon, 3-Jul 7:00 AM ET)
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
Ac Immune SA trades on the NASDAQ stock market under the symbol ACIU.
As of September 27, 2023, ACIU stock price was flat at $3.00 with 34,677 million shares trading.
ACIU has a beta of 0.85, meaning it tends to be less sensitive to market movements. ACIU has a correlation of 0.03 to the broad based SPY ETF.
ACIU has a market cap of $250.59 million. This is considered a Small Cap stock.
Last quarter Ac Immune SA reported $0 in Revenue and -$.22 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .
In the last 3 years, ACIU stock traded as high as $12.61 and as low as $1.68.
ACIU has outperformed the market in the last year with a return of +21.0%, while the SPY ETF gained +18.7%. In the last 3 month period, ACIU beat the market returning +51.5%, while SPY returned -0.9%. However, in the most recent 2 weeks ACIU has underperformed the stock market by returning -10.7%, while SPY returned -4.1%.
ACIU support price is $2.88 and resistance is $3.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACIU stock will trade within this expected range on the day.